Laserfiche WebLink
E-cigarettes: an evidence update <br /> <br />25 <br />Policy implications <br />o From May 2016, following the introduction of the revised TPD, ECs will be more <br />strictly regulated. As detailed elsewhere in the report, the information we present <br />does not indicate widespread problems as a result of EC. Hence, the current <br />regulatory structure appears broadly to have worked well although protecting non - <br />smoking children and ensuring the products on the market are as safe and effective <br />as possible are clearly important goals. New regulations currently planned should <br />be implemented to maximise the benefits of EC whilst minimising these risks. <br /> <br />o An assessment of the impact of the TPD regulations on the UK EC market will be <br />integral to its implementation. This should include the degree to which the <br />availability of safe and effective products might be restricted. <br /> <br />o Much of England’s strategy of tobacco harm reduction is predicated on the <br />availability of medicinally licensed products that smokers want to use. Licensed ECs <br />are yet to appear. A review of the MHRA EC licensing process therefore seems <br />appropriate, including manufacturers’ costs, and potential impact. This could include <br />a requirement for MHRA to adapt the processes and their costs to enable smaller <br />manufacturers to apply, and to speed up the licensing process. The review could <br />also assess potential demand for the EC prescription market and what types of <br />products would be most appropriate to meet that demand. <br />Prevalence in England / GB <br />